tetano
Editor, Senior Moderator
Front Immunol
. 2024 Mar 12:15:1347676.
doi: 10.3389/fimmu.2024.1347676. eCollection 2024. Faecalibacterium duncaniae as a novel next generation probiotic against influenza
Loïc Chollet[SUP] 1 [/SUP], Séverine Heumel[SUP] 1 [/SUP], Lucie Deruyter[SUP] 1 [/SUP], Fabrice Bouilloux[SUP] 2 [/SUP], Lou Delval[SUP] 1 [/SUP], Véronique Robert[SUP] 3 [/SUP], Marie-Hélène Gevaert[SUP] 4 [/SUP], Muriel Pichavant[SUP] 1 [/SUP], Valentin Sencio[SUP] 1 [/SUP], Cyril Robil[SUP] 1 [/SUP], Isabelle Wolowczuk[SUP] 1 [/SUP], Harry Sokol[SUP] 5 6 [/SUP], Sandrine Auger[SUP] 3 [/SUP], Alexandre Douablin[SUP] 2 [/SUP], Philippe Langella[SUP] 3 [/SUP], Jean-Marc Chatel[SUP] 3 [/SUP], Corinne Grangette[SUP] #[/SUP][SUP] 1 [/SUP], François Trottein[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
The gut-lung axis is critical during viral respiratory infections such as influenza. Gut dysbiosis during infection translates into a massive drop of microbially produced short-chain fatty acids (SCFAs). Among them, butyrate is important during influenza suggesting that microbiome-based therapeutics targeting butyrate might hold promises. The butyrate-producing bacterium Faecalibacterium duncaniae (formerly referred to as F. prausnitzii) is an emerging probiotic with several health-promoting characteristics. To investigate the potential effects of F. duncaniae on influenza outcomes, mice were gavaged with live F. duncaniae (A2-165 or I-4574 strains) five days before infection. Supplementation of F. duncaniae was associated with less severe disease, a lower pulmonary viral load, and lower levels of lung inflammation. F. duncaniae supplementation impacted on gut dysbiosis induced by infection, as assessed by 16S rRNA sequencing. Interestingly, F. duncaniae administration was associated with a recovery in levels of SCFAs (including butyrate) in infected animals. The live form of F. duncaniae was more potent that the pasteurized form in improving influenza outcomes. Lastly, F. duncaniae partially protected against secondary (systemic) bacterial infection. We conclude that F. duncaniae might serve as a novel next generation probiotic against acute viral respiratory diseases.
Keywords: Faecalibacterium; SCFAs; influenza; interferons; live biotherapeutic products; microbiota.
. 2024 Mar 12:15:1347676.
doi: 10.3389/fimmu.2024.1347676. eCollection 2024. Faecalibacterium duncaniae as a novel next generation probiotic against influenza
Loïc Chollet[SUP] 1 [/SUP], Séverine Heumel[SUP] 1 [/SUP], Lucie Deruyter[SUP] 1 [/SUP], Fabrice Bouilloux[SUP] 2 [/SUP], Lou Delval[SUP] 1 [/SUP], Véronique Robert[SUP] 3 [/SUP], Marie-Hélène Gevaert[SUP] 4 [/SUP], Muriel Pichavant[SUP] 1 [/SUP], Valentin Sencio[SUP] 1 [/SUP], Cyril Robil[SUP] 1 [/SUP], Isabelle Wolowczuk[SUP] 1 [/SUP], Harry Sokol[SUP] 5 6 [/SUP], Sandrine Auger[SUP] 3 [/SUP], Alexandre Douablin[SUP] 2 [/SUP], Philippe Langella[SUP] 3 [/SUP], Jean-Marc Chatel[SUP] 3 [/SUP], Corinne Grangette[SUP] #[/SUP][SUP] 1 [/SUP], François Trottein[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
- PMID: 38590519
- PMCID: PMC11000806
- DOI: 10.3389/fimmu.2024.1347676
The gut-lung axis is critical during viral respiratory infections such as influenza. Gut dysbiosis during infection translates into a massive drop of microbially produced short-chain fatty acids (SCFAs). Among them, butyrate is important during influenza suggesting that microbiome-based therapeutics targeting butyrate might hold promises. The butyrate-producing bacterium Faecalibacterium duncaniae (formerly referred to as F. prausnitzii) is an emerging probiotic with several health-promoting characteristics. To investigate the potential effects of F. duncaniae on influenza outcomes, mice were gavaged with live F. duncaniae (A2-165 or I-4574 strains) five days before infection. Supplementation of F. duncaniae was associated with less severe disease, a lower pulmonary viral load, and lower levels of lung inflammation. F. duncaniae supplementation impacted on gut dysbiosis induced by infection, as assessed by 16S rRNA sequencing. Interestingly, F. duncaniae administration was associated with a recovery in levels of SCFAs (including butyrate) in infected animals. The live form of F. duncaniae was more potent that the pasteurized form in improving influenza outcomes. Lastly, F. duncaniae partially protected against secondary (systemic) bacterial infection. We conclude that F. duncaniae might serve as a novel next generation probiotic against acute viral respiratory diseases.
Keywords: Faecalibacterium; SCFAs; influenza; interferons; live biotherapeutic products; microbiota.